New Brunswick, New Jersey, United States; Houston, Texas, United States, November 19, 2026
Johnson & Johnson has announced the first commercial installation of its OTTAVA™ Robotic Surgical System at Memorial Hermann-Texas Medical Center in Houston, Texas, marking an important milestone in the commercial launch of its next-generation soft-tissue robotic surgery platform. Under an early access commercial programme, Memorial Hermann will become the first hospital in the United States to use the system. The installation builds on a longstanding clinical collaboration between Johnson & Johnson and Memorial Hermann, which previously participated in the system’s clinical evaluation programme. The announcement represents a significant development in the advancement of robotic-assisted general surgery, as healthcare providers increasingly explore technologies that can support surgical precision, improve operating room workflows and address growing demands on hospital resources. The OTTAVA platform combines a table-integrated design, robotic instrumentation and software-enabled capabilities intended to support surgeons and operating room teams across a range of procedures. The commercial launch follows the system’s U.S. Food and Drug Administration (FDA) De Novo authorization in July 2026, allowing its use in ten general surgery procedures involving the upper abdomen.
First Commercial Installation Marks a Milestone in Robotic Surgery
The selection of Memorial Hermann-Texas Medical Center as the first commercial installation site reflects the hospital’s involvement in the development and clinical evaluation of OTTAVA. The medical centre served as a clinical trial site under the Investigational Device Exemption (IDE) programme, which supported the regulatory authorization process. The system was also evaluated in the context of Roux-en-Y gastric bypass surgery, with clinical collaboration helping inform its development and practical application. Johnson & Johnson stated that working with early commercial customers will help the company understand real-world requirements and support the introduction of the technology into hospital environments. The collaboration is also expected to contribute to the generation of clinical data and real-world evidence as the platform moves into broader use. Erik Wilson, M.D., a surgeon at UTHealth Houston and Memorial Hermann-Texas Medical Center, served as the lead investigator for the FORTE clinical study and highlighted the importance of collaboration in bringing new surgical technologies into clinical practice. The first commercial installation is therefore not only a product-launch milestone but also an opportunity to continue evaluating how integrated robotic technology fits into established surgical workflows.
Four Robotic Arms Integrated Into a Surgical Table
A central feature of the OTTAVA Robotic Surgical System is its table-integrated architecture, which incorporates four robotic arms into a standard-sized surgical table. This design aims to address operating room space constraints and the workflow complexity associated with robotic-assisted procedures. By integrating the robotic platform with the surgical table, the system is designed to help surgical teams manage equipment positioning, maintain procedural momentum and potentially improve the use of available operating room space. OTTAVA also incorporates software-controlled automation capabilities, next-generation robotic instruments and compatibility with the Polyphonic™ Digital Ecosystem. These features are intended to support the interaction between surgeons, instruments and digital technologies during procedures. Johnson & Johnson has positioned the platform as a new category of soft-tissue robotics, with a design focused on the practical needs of hospitals and surgical teams. Its integrated architecture may offer healthcare facilities another option for incorporating robotic assistance into general surgery, although its impact on operating room efficiency and patient outcomes will need to be assessed through clinical experience and further evidence.
FDA Authorization Covers Ten General Surgery Procedures
The commercial installation follows the FDA’s De Novo authorization granted in July 2026, making OTTAVA the world’s first FDA-authorized table-integrated soft-tissue robotic surgical system, according to Johnson & Johnson. The authorization covers ten general surgery procedures, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve surgery, small bowel resection, appendectomy, lysis of adhesions, fundoplication and hiatal hernia repair. This regulatory milestone established the system’s authorized use across several procedures involving the upper abdomen and provided the basis for its commercial introduction in the United States. Johnson & Johnson plans to continue the launch with selected U.S. healthcare customers while focusing on early customer experience and evaluating the platform in additional indications. The company aims to work alongside hospitals and surgical teams to support adoption, assess clinical workflows and develop further evidence regarding the technology’s role in robotic-assisted surgery. The first installation at Memorial Hermann represents an important step in this process, bringing the OTTAVA platform from clinical development into an early commercial healthcare setting. As adoption progresses, clinical experience, workflow evaluation and real-world evidence will be important in determining its broader contribution to modern surgical care.
Source: Johnson & Johnson press release



